Oculis Shares Drop Following Phase 3 Trial Failures
Oculis Holding (OCS) shares fell by approximately 35% in early Monday trading after previously dropping around 23% on May 29, following the failure of two phase 3 trials for its diabetic macular edema candidate. The studies did not meet primary or secondary endpoints.
Tickers: $OCS
Topics: biotech drug_development ophthalmology